如瑞迪博士 RDY 深 沪
等待开盘 08-10 09:30:00 美东时间
12.205
+0.095
+0.78%
华盛通- 最 高12.26
- 今 开12.19
- 成交量 230.08万股
- 最 低 11.97
- 昨 收 12.11
- 总市值 202.60万
- 52周最高 15.67
- 市盈率 静 6.42
- 换手率 1386.00%
- 52周最低 11.36
- 委 比 -9.07%
- 总股本 0.00亿
- 历史最高 84.46
- 量 比 1.04
- 振 幅 2.39%
- 历史最低 11.36
- 每 手 1
- 风险率 0.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Dr. Reddy's Sank: Profit Plunge, Semaglutide Setback And Trump's Tariff Threat
Dr. Reddy's (RDY) stock drops after missing Q1 FY27 earnings & revenue estimates. Semaglutide issues & Trump tariff plans weigh on shares.
07-23 02:12
Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push
Dr. Reddy's launched generic Semaglutide Injection in Canada, expanding its GLP-1 portfolio and strengthening its affordable diabetes treatment presence.
05-17 03:17
Dr. Reddy's Laboratories Russian Unit Fined RUB 9.27M by Russia Regulator
https://www.sec.gov/Archives/edgar/data/1135951/000157587226000247/rdy0885_6k.htm
04-15 19:58
India's Generic Wave Hits Ozempic And Wegovy As Prices Drop Sharply
India's drugmakers roll out low-cost copies for Novo Nordisk's semaglutide, slashing prices up to 70% as analysts weigh global market disruption risks.
03-23 21:00
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
Alvotech and Dr. Reddy’s collaborate to develop and commercialize a biosimilar of Keytruda® (pembrolizumab), aiming to expand global access to cost-effective cancer treatment. This partnership leverages both companies' expertise in biosimilars, enhancing development and market reach.
2025-06-05 06:55
Dr. Reddy's Laboratories Agreed To Partially Defer A Milestone Payment From Citius Oncology, Inc., Due On September 9, 2024, Upon FDA Approval Of LYMPHIR, Without Penalty, Pending Further Discussions, As Per Their 2021 Asset Purchase Agreement
Pending further discussions with Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories, Ltd. (collectively, "Dr. Reddy's"), Dr. Reddy's agreed to a partial deferral without penalty of a milestone payment
2024-09-13 20:40
Sector Update: Health Care Stocks Decline Late Afternoon
04:00 PM EDT, 09/03/2024 (MT Newswires) -- Health care stocks fell late Tuesday afternoon with the NYSE Health Care Index shedding 0.5% and the Health Care Select Sector SPDR Fund (XLV) down 0.3%. The iShares Biotechnology ETF (IBB) dropped 1.8%. In corporate news, TC BioPharm (TCBP) shares jumped 2...
2024-09-04 04:00
Dr. Reddy's Laboratories' Atomoxetine Hydrochloride Capsules Suspended in China
10:06 AM EDT, 09/03/2024 (MT Newswires) -- Dr. Reddy's Laboratories (RDY) said in a regulatory filing Tuesday that China's National Medical Products Administration has issued an order suspending the import, sale, and use of the company's atomoxetine hydrochloride capsules, effective Aug. 30, for fai...
2024-09-03 22:06
Dr. Reddy's Receives FDA Form 483 With Three Observations Following Inspection At Srikakulam Facility
Dr. Reddy's Receives FDA Form 483 With Three Observations Following Inspection At Srikakulam Facility
2024-08-23 21:31
Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services, And Kainomyx Sign Non-Binding MoU For Joint Development Of Affordable Anti-Malarial Drug
Malaria is a life-threatening public health issue, particularly in low- and middle-income countries. There is a need for an effective, affordable, and accessible preventive and/or treatment medication. This potential partnership is a step towards this cause This potential partnership aims to bring t...
2024-08-21 02:43
